S8 Ep19: FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

from OncLive® On Air · host OncLive® On Air

Dr Strickler discusses the FDA approval of tucatinib plus trastuzumab in metastatic colorectal cancer, key efficacy and safety findings from the MOUNTAINEER trial, and ongoing research seeking to address remaining unmet needs in this population.

Episode metadata supplied by the publisher feed · Published Feb 6, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

S8 Ep19: FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

0:00 9:36

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 9 minutes long.

When was this OncLive® On Air episode published?

This episode was published on February 6, 2023.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!